An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2025-07-01
Sarja:	EBioMedicine
Aiheet:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Linkit:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!